At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 338 enrolled
Drug / intervention
Rabeprazole +3 moredrug
Likely dose
Rabeprazole 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia
In Brief
A Phase 2 clinical trial evaluating Rabeprazole and Placebo for Functional Dyspepsia. Completed, enrolled 338 participants across 46 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFunctional Dyspepsia
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartApr 2010
Primary CompletionAug 2011
TodayJul 2026
First PostedMar 18, 2010
Enrollment StartApr 1, 2010
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.3 years ago
Interventions
Rabeprazoledrug
Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
Rabeprazoledrug
Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
Rabeprazoledrug
Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
Placebodrug
Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.